top of page

Investigating the efficacy, safety, and tolerability of ML-004 in autistic adolescents 

We are working with Maplight and other sites around Australia, Canada, and the United States, to investigate the safety, tolerability, and efficacy of a pharmaceutical therapy called ML-004.

​

We are looking to find out whether ML-004
might address the characteristics of autism that can make social interaction challenging.

Recruitment

To be eligible, participants must be:

  • Be aged 12-17 years old 

  • Have an autism diagnosis

  • Have a relative, housemate, friend, or other study partner to assist during the study and attend clinic visits

​

There are additional requirements for participation. The study staff will explain the complete list of requirements.

​

This study is currently OPEN. Register your interest below. â€‹

bottom of page